Sort
82,697 grants matching “vaccine development”
Optimization of a Therapeutic HIVSIV Multi-Antigen DNA Vaccine
$968,957Kenneth C Bagley · Profectus Biosciences, Inc. · R44 · FY2016 · AI
Structural studies of native-like SOSIP trimers
$968,907Ian A Wilson · Weill Medical Coll Of Cornell Univ · P01 · FY2018 · AI
Structural studies of native-like SOSIP trimers
$968,906Ian A Wilson · Weill Medical Coll Of Cornell Univ · P01 · FY2017 · AI
Hispanic, black and pacific islandeR perspectives on COVID-19 oUtreach Strategies and patient centered outcomes (HeAR US)
$968,834Todd B Seto · Queen'S Medical Center · U01 · FY2022 · FD
Immunology of Acute and Chronic Viral Hepatitis
$968,816Barbara Rehermann · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2025 · DK
Acute Hepatitis C Infection in Young Injectors
$968,688Kimberly Page · University Of California, San Francisco · R01 · FY2010 · DA
Monoclonal Antibody to Combat Pseudomonas Aeruginosa
$968,643Joanna B. Goldberg · Emory University · R01 · FY2024 · AI
Characterization of the Pharmacokinetic/Pharmacodynamic (PK/PD) Profile of a Candidate HIV Prevention Drug in Rhesus Macaques
$968,613Peter Silvera · Advanced Bioscience Laboratories, Inc. · N01 · FY2022 · AI
UCSF-UCB Tuberculosis Research Advancement Center (TRAC)
$968,482Payam Nahid · University Of California, San Francisco · P30 · FY2022 · AI
UCSF-UCB Tuberculosis Research Advancement Center (TRAC)
$968,462Payam Nahid · University Of California, San Francisco · P30 · FY2023 · AI
UCSF-UCB Tuberculosis Research Advancement Center (TRAC)
$968,441Payam Nahid · University Of California, San Francisco · P30 · FY2024 · AI
UCSF-UCB Tuberculosis Research Advancement Center (TRAC)
$968,419Payam Nahid · University Of California, San Francisco · P30 · FY2025 · AI
A glycolipid adjuvant to promote dose sparing, accelerate immunization schedules and extend durability of high-level protection with an attenuated, live sporozoite malaria vaccine
$968,360Stephen Lev Hoffman · Sanaria, Inc. · R44 · FY2024 · AI
Co-creation of digital tools to enhance young adult minority participation in COVID-19 trials
$968,302Joshua Yang · California State University Fullerton · U01 · FY2022 · FD
A glycolipid adjuvant to promote dose sparing, accelerate immunization schedules and extend durability of high-level protection with an attenuated, live sporozoite malaria vaccine
$968,151Stephen Lev Hoffman · Sanaria, Inc. · R44 · FY2023 · AI
Coronavirus vaccine development
$968,136Barney Graham · National Institute Of Allergy And Infectious Diseases · ZIA · FY2016 · AI
Plant Viruses as Platforms for Biomaterials
$968,133John Johnson · Scripps Research Institute, The · R01 · FY2006 · EB
Optimization and Advanced Proof-of-Concept Studies of a Listeria-vectored Multi-Antigenic Vaccine against Tuberculosis
$968,076Marcus Aaron Horwitz · University Of California Los Angeles · R01 · FY2018 · AI
Rational design and targeted selection of DNA-scaffolded nicotine vaccines
$967,930Yung Chang · Arizona State University-Tempe Campus · R01 · FY2014 · DA
Pacific Center for Emerging Infectious Diseases Research
$967,630Vivek Ramchandra Nerurkar · University Of Hawaii At Manoa · P30 · FY2022 · GM
The Empilisweni Center for Women's Health - Advancing Implementation of Equitable Cervical Cancer Control
$967,556Delivette Castor · Columbia University Health Sciences · U54 · FY2023 · CA
High-throughput immunoproteomics for cancer biomarker discovery
$967,342Joshua Labaer · Arizona State University-Tempe Campus · U2C · FY2025 · CA
Nipah & Hendra Virus Nonhuman Primate Model & Therapeutics Development
$967,287Thomas William Geisbert · University Of Texas Med Br Galveston · U01 · FY2013 · AI
A novel vaccine against multidrug-resistant gonorrhea
$967,287Sanjay Ram · Univ Of Massachusetts Med Sch Worcester · R01 · FY2019 · AI
Pregnancy Malaria Vaccine development
$967,251Patrick Duffy · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI